Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24856066 | 0.84 | GRIN2D (0.36) | — | |
| SCHEMBL20317542 | 0.83 | PIK3CD (0.38) | CYP2D6SMN1; SMN2PIK3CDCYP2C9TSHR | |
| SCHEMBL3420105 | 0.82 | PIK3CD (0.47) | CYP2D6SMN1; SMN2PIK3CDALDH1A1 | |
| SCHEMBL20314535 | 0.80 | — | — | |
| SCHEMBL24411695 | 0.78 | CYP2D6 (0.54) | CYP2D6SMN1; SMN2PIK3CDCYP2C9TSHR | |
| SCHEMBL22402428 | 0.75 | PIK3CD (0.41) | CYP2D6SMN1; SMN2PIK3CD | |
| SCHEMBL24856302 | 0.74 | PIK3CD (0.40) | CYP2D6SMN1; SMN2PIK3CD | |
| SCHEMBL21934376 | 0.71 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2PIK3CDCYP2C9TSHR | |
| SCHEMBL17281968 | 0.71 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2CYP2C9TSHRALDH1A1 | |
| SCHEMBL19323772 | 0.71 | CYP2D6 (0.46) | CYP2D6SMN1; SMN2PIK3CDCYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | CYP2D6 4807/4885SMN1; SMN2 881/4885PIK3CD 4021/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | CYP2D6 4807/4885SMN1; SMN2 881/4885PIK3CD 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.